{
  "source": "nccn-bladder",
  "version": "1.2025",
  "description": "Gold set for NCCN Bladder Cancer Guidelines ctDNA/MRD recommendations",
  "expectedExtractions": [
    {
      "id": "nccn-bladder-surveillance-1",
      "type": "recommendation",
      "cancerType": "bladder",
      "clinicalSetting": "surveillance",
      "evidenceLevel": "Category 2A",
      "keyQuote": "ctDNA monitoring after radical cystectomy",
      "mustContain": ["ctDNA", "surveillance", "bladder"],
      "mustNotContain": []
    },
    {
      "id": "nccn-bladder-mibc-1",
      "type": "recommendation",
      "cancerType": "bladder",
      "clinicalSetting": "adjuvant",
      "evidenceLevel": "Category 2A",
      "keyQuote": "MRD detection in muscle-invasive bladder cancer",
      "mustContain": ["MRD", "muscle-invasive"],
      "mustNotContain": []
    },
    {
      "id": "nccn-bladder-immuno-1",
      "type": "recommendation",
      "cancerType": "bladder",
      "clinicalSetting": "treatment_response",
      "evidenceLevel": "Category 2B",
      "keyQuote": "ctDNA for immunotherapy response assessment",
      "mustContain": ["ctDNA", "immunotherapy", "response"],
      "mustNotContain": []
    }
  ],
  "metadata": {
    "createdAt": "2026-02-02",
    "createdBy": "claude",
    "totalExpectedItems": 3,
    "targetAccuracy": 0.8
  }
}
